CNS PHARMACEUTICALS INC (CNSP)
US18978H3003 - Common Stock
We assign a fundamental rating of 1 out of 10 to CNSP. CNSP was compared to 192 industry peers in the Pharmaceuticals industry. CNSP may be in some trouble as it scores bad on both profitability and health. CNSP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CNSP had negative earnings in the past year.
In the past year CNSP has reported a negative cash flow from operations.
In the past 5 years CNSP always reported negative net income.
CNSP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CNSP has a Return On Assets of -230.21%. This is amonst the worse of the industry: CNSP underperforms 91.30% of its industry peers.
CNSP's Return On Equity of -508.80% is on the low side compared to the rest of the industry. CNSP is outperformed by 81.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -230.21% | ||
| ROE | -508.8% | ||
| ROIC | N/A |
ROA(3y)-463.63%
ROA(5y)-299.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CNSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, CNSP has less shares outstanding
CNSP has less shares outstanding than it did 5 years ago.
The debt/assets ratio for CNSP is higher compared to a year ago.
2.2 Solvency
CNSP has an Altman-Z score of -21.37. This is a bad value and indicates that CNSP is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -21.37, CNSP is not doing good in the industry: 86.96% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.01 indicates that CNSP is not too dependend on debt financing.
CNSP has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: CNSP outperforms 58.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -21.37 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNSP has a Current Ratio of 1.82. This is a normal value and indicates that CNSP is financially healthy and should not expect problems in meeting its short term obligations.
CNSP's Current ratio of 1.82 is on the low side compared to the rest of the industry. CNSP is outperformed by 63.59% of its industry peers.
CNSP has a Quick Ratio of 1.82. This is a normal value and indicates that CNSP is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.82, CNSP perfoms like the industry average, outperforming 41.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
CNSP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.37%.
EPS 1Y (TTM)-30.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 25.36% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.92%
EPS Next 2Y40.27%
EPS Next 3Y25.36%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CNSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNSP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CNSP's earnings are expected to grow with 25.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.27%
EPS Next 3Y25.36%
5. Dividend
5.1 Amount
No dividends for CNSP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CNS PHARMACEUTICALS INC
NASDAQ:CNSP (1/3/2025, 8:00:01 PM)
After market: 0.1529 +0.03 (+24.31%)0.123
+0.01 (+5.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.45%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner Change0%
Market Cap7.07M
Analysts82.86
Price Target0.51 (314.63%)
Short Float %2.35%
Short Ratio0.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)94.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.11 | ||
| P/tB | 2.11 | ||
| EV/EBITDA | N/A |
EPS(TTM)-80.15
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -230.21% | ||
| ROE | -508.8% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-463.63%
ROA(5y)-299.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 66.06% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z | -21.37 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.85%
EPS Next Y92.92%
EPS Next 2Y40.27%
EPS Next 3Y25.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.4%
OCF growth 3YN/A
OCF growth 5YN/A